# A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

> **NCT07285005** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Kaken Pharmaceutical** · enrollment: 150 (estimated)

## Conditions studied

- Venous Malformations
- Lymphatic Malformations
- Klippel-Trenaunay Syndrome
- CLOVES Syndrome

## Interventions

- **DRUG:** KP-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07285005
- **Lead sponsor:** Kaken Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285005, "A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07285005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*